Achaogen Inc (AKAO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Achaogen Inc (AKAO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010840
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company is developing plazomicin for the treatment of serious bacterial infections due to MDR Enterobacteriaceae. Its pipeline products include C-scape, lpxC inhibitors, and others. Achaogen’s C-Scape is a combination of an approved beta-lactam and an approved beta-lactamase inhibitor that can treat patients with complex urinary tract infections due to MDR pathogens. The company collaborates with the antibacterial drug development companies and academic researchers in the field of antibiotic pharmacology. Achaogen is headquartered in San Francisco, California, the US.

Achaogen Inc (AKAO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Achaogen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Achaogen Raises US$19 Million In Venture Financing 11
Licensing Agreements 12
Achaogen Enters into Licensing Agreement with Crystal Bioscience 12
Achaogen Enters into Licensing Agreement with Trianni 13
Equity Offering 14
Achaogen Raises USD112.5 Million in Public Offering of Shares 14
Achaogen to Raise USD10 Million in Private Placement of Shares 16
Achaogen Receives USD5.3 Million in Public Offering of Shares 17
Achaogen Raises USD101 Million in Public Offering of Shares 18
Achaogen Raises USD25 Million in Private Placement of Shares 20
Achaogen Completes IPO For US$82.8 Million 22
Achaogen Inc – Key Competitors 23
Achaogen Inc – Key Employees 24
Achaogen Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2017: Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update 26
Aug 03, 2017: Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update 28
May 08, 2017: Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update 30
Mar 14, 2017: Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 32
Nov 07, 2016: Achaogen Reports Third Quarter 2016 Financial Results 34
Aug 08, 2016: Achaogen Reports Second Quarter 2016 Financial Results and Provides Corporate Update 35
May 05, 2016: Achaogen Reports First Quarter 2016 Financial Results 37
Mar 15, 2016: Achaogen Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 38
Corporate Communications 40
Sep 18, 2017: Achaogen Adds Liz Bhatt as Chief Business Officer 40
Jul 13, 2017: Achaogen Appoints Dr. Karen Bernstein to its Board of Directors 41
Feb 27, 2017: Achaogen Adds Janet Dorling as Chief Commercial Officer 42
Feb 23, 2017: Achaogen Announces Leadership Promotions 43
Jan 05, 2017: Achaogen appoints new board member 44
Jun 03, 2016: Achaogen Adds Tobin Schilke as Chief Financial Officer 45
Government and Public Interest 46
May 05, 2017: Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria 46
Product News 47
07/25/2017: Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections 47
07/15/2016: Achaogen to Host Key Opinion Leader Meeting on Multi-Drug Resistant Infections on July 19, 2016 in New York 48
06/20/2016: Achaogen Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens 49
06/09/2016: Achaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting 51
Mar 01, 2017: Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company’s R&D Day 52
Clinical Trials 53
Jun 01, 2017: Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate 53
Sep 01, 2016: Achaogen Completes Patient Enrollment in Phase 3 EPIC Clinical Trial of Plazomicin 54
Jun 02, 2016: Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin 55
Apr 05, 2016: Achaogen Announces Acceleration of Expected Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin 56
Jan 11, 2016: Achaogen Announces Enrollment of First Patient in EPIC, a Phase 3 Clinical Trial for the Treatment of Complicated Urinary Tract Infections With Plazomicin 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Achaogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Achaogen Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Achaogen Raises US$19 Million In Venture Financing 11
Achaogen Enters into Licensing Agreement with Crystal Bioscience 12
Achaogen Enters into Licensing Agreement with Trianni 13
Achaogen Raises USD112.5 Million in Public Offering of Shares 14
Achaogen to Raise USD10 Million in Private Placement of Shares 16
Achaogen Receives USD5.3 Million in Public Offering of Shares 17
Achaogen Raises USD101 Million in Public Offering of Shares 18
Achaogen Raises USD25 Million in Private Placement of Shares 20
Achaogen Completes IPO For US$82.8 Million 22
Achaogen Inc, Key Competitors 23
Achaogen Inc, Key Employees 24

★海外企業調査レポート[Achaogen Inc (AKAO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Power Finance Corp Ltd (PFC):企業の財務・戦略的SWOT分析
    Power Finance Corp Ltd (PFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Subsea 7 SA (SUBC):企業の財務・戦略的SWOT分析
    Subsea 7 SA (SUBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Aushon BioSystems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that offers biomarker measurement and analysis products. The company provides biomarker therapeutic areas in microarray printing technology. Its products include ciraplex assay, cirascan imaging and cirasoft analysis and cira servic …
  • Enbridge Inc.:戦略・SWOT・企業財務分析
    Enbridge Inc. - Strategy, SWOT and Corporate Finance Report Summary Enbridge Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • United Rentals Inc:戦略・SWOT・企業財務分析
    United Rentals Inc - Strategy, SWOT and Corporate Finance Report Summary United Rentals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Exxon Mobil Corp (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petro …
  • Propanc Biopharma Inc (PPCB):製薬・医療:M&Aディール及び事業提携情報
    Summary Propanc Biopharma Inc (Propanc), formerly Propanc Health Group Corp, is a clinical stage biopharmaceutical company, which manufactures products for the treat of metastatic, pancreatic, ovarian and colorectal cancers. The company’s lead product candidate, PRP, a once-a-day intravenous formula …
  • Alabama Power Co-エネルギー分野:企業M&A・提携分析
    Summary Alabama Power Company (Alabama Power), a subsidiary of Southern Company, is a vertically-integrated utility that undertakes the generation, transmission, distribution, procurement and sale of electricity. It generates electricity from coal, hydro, natural gas, oil and nuclear sources. Alabam …
  • Cosucra Groupe Warcoing SA:企業の戦略・SWOT・財務情報
    Cosucra Groupe Warcoing SA - Strategy, SWOT and Corporate Finance Report Summary Cosucra Groupe Warcoing SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Reliance Infrastructure Ltd (RELINFRA):企業の財務・戦略的SWOT分析
    Reliance Infrastructure Ltd (RELINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Ignyta Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc, a subsidiary of F. Hoffmann-La Roche Ltd, is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic technology (Rx/Dx). …
  • Union Bank of Taiwan:企業の戦略・SWOT・財務情報
    Union Bank of Taiwan - Strategy, SWOT and Corporate Finance Report Summary Union Bank of Taiwan - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Fluidigm Corp (FLDM):企業の財務・戦略的SWOT分析
    Summary Fluidigm Corp (Fluidigm), formerly Mycometrix Corp, develops, manufactures, and markets life science analytical and preparatory systems for mass cytometry, high-throughput genomics, and single-cell genomics markets. The company offers analytical systems and instruments, preparatory instrumen …
  • Intact Financial Corporation:戦略・SWOT・企業財務分析
    Intact Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Intact Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Nordson Corporation:企業のM&A・事業提携・投資動向
    Nordson Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nordson Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Aldi Einkauf GmbH & Co oHG:戦略・SWOT・企業財務分析
    Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report Summary Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Xcel Energy Inc (XEL)-エネルギー分野:企業M&A・提携分析
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • Systematic A/S:企業の戦略・SWOT・財務分析
    Systematic A/S - Strategy, SWOT and Corporate Finance Report Summary Systematic A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • GulfMark Offshore Inc (GLF):企業の財務・戦略的SWOT分析
    Summary GulfMark Offshore Inc (GulfMark Offshore), formerly New GulfMark Offshore Inc is an oil and gas company that offers oil and gas, and marine transportation services. It owns, operates, and manages fleet of vessels offering marine specialty services to offshore oil and natural gas drilling rig …
  • Northern Ireland Electricity Networks Ltd:企業の戦略的SWOT分析
    Northern Ireland Electricity Networks Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆